Alexion mulls producing pipeline drugs in Ireland

Five vials of Alexion's Soliris
Soliris vials

A senior executive with Alexion ($ALXN), the maker of orphan drug Soliris, said the company is taking a hard look at locating facilities to produce its new pipeline of drugs in Ireland.

“We are planning where and how production for our pipeline of drugs will happen and Ireland is being considered,” Julie O’Neill, the company’s executive vice president of global operations, told the Irish Independent. “I don’t want to say too much as it is still early days.”

The company has earmarked three-quarters of a billion dollars in investment in the country since it set up shop in 2013, the newspaper said.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Sites for new facilities under consideration include the Dublin area and Athlone, O’Neill said. 

Currently, Alexion has a vial-filling plant in Athlone and an operation in College Park in Blanchardstown where it is spending $507 million to build its first biologics plant outside the U.S. When that facility is completed, Alexion will employ about 500 people in Ireland. 

Alexion is best known for Soliris, which is often described as the most expensive drug in the world. The drug, which costs about $400,000 a year per patient, is used to treat paroxysmal nocturnal hemoglobinuria, a rare and fatal form of blood disease.

- check out the Irish Independent story

Related Articles:
Rare-disease specialist Alexion hails progress on Sanfilippo B drug
Alexion sues Canada over Soliris price cut attempt as drug cost debate explodes on center stage
Alexion buys vial-filling facility in Ireland

Image courtesy of Alexion


Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.